We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New AI Algorithms Enable Diagnosis of Difficult Cancers

By LabMedica International staff writers
Posted on 07 Dec 2023
Print article
Image: New AI algorithms can aid diagnosis of clinically difficult-to-interpret cancerous tumors (Photo courtesy of CLARIFY)
Image: New AI algorithms can aid diagnosis of clinically difficult-to-interpret cancerous tumors (Photo courtesy of CLARIFY)

A team of European researchers and companies, led by the Valencia Polytechnic University (UPV, Valencia, Spain), through the CVBLab-HUMAN-tech group, has developed novel artificial intelligence (AI) algorithms to aid the diagnosis and treatment of cancerous tumors that are difficult to interpret clinically. This is one of the main results of the CLARIFY project, which is now in its final months of execution.

CLARIFY is an innovative, multinational, multi-sectorial, and multidisciplinary research initiative with a focus on developing a robust automated digital diagnostic environment based on AI and cloud-oriented data algorithms. The goal is to streamline the interpretation and diagnosis of whole-slide-images (WSIs) globally, to optimize the advantages of digital pathology, and to support pathologists in their routine tasks. The project has concentrated on specific and difficult-to-diagnose cancer types to evaluate the effectiveness of the tools and methods it has developed. These include Triple Negative Breast Cancer (TNBC), High-risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC), and Spitzoid Melanocytic Lesions (SML), representing the diverse challenges present in cancer diagnosis.

Furthermore, the CLARIFY project has yielded additional noteworthy results, such as the creation of comprehensive databases for the studied cancers. These databases are poised to be valuable assets for the medical and scientific communities. The project has also made progress in the secure handling of data in cloud environments, addressing the unique requirements of the healthcare sector. This includes several practical applications within the project's framework, enhancing data security and management.

“In all three cases, the diagnosis is complex and challenging, which we are already addressing with this project,” said Valery Naranjo, project leader. “With these algorithms, we are taking another step forward in facilitating the interpretation of histological images and, ultimately, the diagnosis of these types of cancer for medical professionals.”

Related Links:
Valencia Polytechnic University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.